SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NPSP NPS Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (335)10/2/2013 3:29:47 PM
From: tuck   of 363
 
Ronacaleret: Not much has been said about this calcilytic program with GSK, so I went looking. GSK not exactly flying through development. They publicly gave up on osteoporosis, and they seem to have given up on other bone disorders, since the completed studies in those areas were either terminated for futility or completed so long ago that lack of news suggests futility. But the most recently completed study is in stem cell transplant. If we hear nothing in the next year, I think we can assume the compound & GSK calcilytic program is dead. Assigning no value to it.

The compounds assigned to NPS from the collaboration are still listed as preclinical. They got to P2 for osteoporosis. NPS not exactly flying on development of these, either. They haven't mentioned narrowing their focus to late stage products and slowing other programs -- that I have noticed -- but that seems to be the situation. Assigning no value to them, either. So GATTEX and Natpara.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News